Th1 cytokines are more effective than Th2 cytokines at licensing anti-tumour functions in CD40-activated human macrophages in vitro

European Journal of Immunology

Volumn 44, Issue 1, 2014, Pages 162-172

  Luheshi, Nadia ^a   Davies, Gareth ^a   Poon, Edmund ^a   Wiggins, Kimberley ^a   Mccourt, Matthew ^a   Legg, James ^a  

^a MEDIMMUNE   (United States)

Author keywords

CD40; Macrophage; Polarisation; Th1 2; Tumour

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; CYTOKINE; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; IN VITRO STUDY; MACROPHAGE; MACROPHAGE CULTURE; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL CULTURE; CELLULAR IMMUNITY; CYTOTOXICITY; DISEASE MODEL; IMMUNOLOGY; MACROPHAGE ACTIVATION; METABOLISM; NEOPLASMS; PROCEDURES; TH1 TH2 BALANCE;

ANIMALS; ANTIGENS, CD40; ANTIGENS, NEOPLASM; CD40 LIGAND; CELLS, CULTURED; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; MACROPHAGE ACTIVATION; MACROPHAGES; NEOPLASMS; TH1 CELLS; TH1-TH2 BALANCE; TH2 CELLS;

EID: 84892467214     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201343351     Document Type: Article

References (48)

1. Mosser, D. M. and Edwards, J. P., Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008. 8: 958-969.
2. Biswas, S. K. and Mantovani, A., Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010. 11: 889-896.
3. Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stange, G., Van den Bossche, J., Mack, M. et al., Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010. 70: 5728-5739.
4. Qian, B. Z. and Pollard, J. W., Macrophage diversity enhances tumor progression and metastasis. Cell 2010. 141: 39-51.
5. Stout, R. D., Jiang, C., Matta, B., Tietzel, I., Watkins, S. K. and Suttles, J., Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J. Immunol. 2005. 175: 342-349.
6. Guiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G. and Colombo, M. P., Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 2005. 65: 3437-3446.
7. Elgueta, R., Benson, M. J., de Vries, V. C., Wasiuk, A., Guo, Y. and Noelle, R. J., Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 2009. 229: 152-172.
8. French, R. R., Chan, H. T., Tutt, A. L. and Glennie, M. J., CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 1999. 5: 548-553.
9. Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R. and Melief, C. J., T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998. 393: 480-483.
10. Vonderheide, R. H., Flaherty, K. T., Khalil, M., Stumacher, M. S., Bajor, D. L., Hutnick, N. A., Sullivan, P. et al., Clinical activity and immune modulation in cancer patients treated with CP-870, 893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 2007. 25: 876-883.
11. Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D. et al., CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011. 331: 1612-1616.
12. Tong, A. W., Papayoti, M. H., Netto, G., Armstrong, D. T., Ordonez, G., Lawson, J. M. and Stone, M. J., Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin. Cancer Res. 2001. 7: 691-703.
13. Jackaman, C., Cornwall, S., Graham, P. T. and Nelson, D. J., CD40-activated B cells contribute to mesothelioma tumor regression. Immunol. Cell Biol. 2011. 89: 255-267.
14. Hamzah, J., Nelson, D., Moldenhauer, G., Arnold, B., Hammerling, G. J. and Ganss, R., Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. J. Clin. Invest. 2008. 118: 1691-1699.
15. Johnson, E. E., Buhtoiarov, I. N., Baldeshwiler, M. J., Felder, M. A., Van Rooijen, N., Sondel, P. M. and Rakhmilevich, A. L., Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice. J. Immunother. 2011. 34: 76-84.
16. Weiss, J. M., Ridnour, L. A., Back, T., Hussain, S. P., He, P., Maciag, A. E., Keefer, L. K. et al., Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. J. Exp. Med. 2010. 207: 2455-2467.
17. Lum, H. D., Buhtoiarov, I. N., Schmidt, B. E., Berke, G., Paulnock, D. M., Sondel, P. M. and Rakhmilevich, A. L., In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages. J. Leukoc. Biol. 2006. 79: 1181-1192.
18. Rakhmilevich, A. L., Buhtoiarov, I. N., Malkovsky, M. and Sondel, P. M., CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors. Cancer Immunol. Immunother. 2008. 57: 1151-1160.
19. Buhtoiarov, I. N., Lum, H. D., Berke, G., Sondel, P. M. and Rakhmilevich, A. L., Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J. Immunol. 2006. 176: 309-318.
20. Wu, Q. L., Buhtoiarov, I. N., Sondel, P. M., Rakhmilevich, A. L. and Ranheim, E. A., Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia. J. Immunol. 2009. 182: 6771-6778.
21. Rakhmilevich, A. L., Alderson, K. L. and Sondel, P. M., T-cell-independent antitumor effects of CD40 ligation. Int. Rev. Immunol. 2012. 31: 267-278.
22. Turner, J. G., Rakhmilevich, A. L., Burdelya, L., Neal, Z., Imboden, M., Sondel, P. M. and Yu, H., Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J. Immunol. 2001. 166: 89-94.
23. Uno, T., Takeda, K., Kojima, Y., Yoshizawa, H., Akiba, H., Mittler, R. S., Gejyo, F. et al., Eradication of established tumors in mice by a combination antibody-based therapy. Nat. Med. 2006. 12: 693-698.
24. Diehl, L., den Boer, A. T., Schoenberger, S. P., van der Voort, E. I., Schumacher, T. N., Melief, C. J., Offringa, R. et al., CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 1999. 5: 774-779.
25. Murphy, W. J., Welniak, L., Back, T., Hixon, J., Subleski, J., Seki, N., Wigginton, J. M. et al., Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J. Immunol. 2003. 170: 2727-2733.
26. Ito, D., Ogasawara, K., Iwabuchi, K., Inuyama, Y. and Onoe, K., Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb. J. Immunol. 2000. 164: 1230-1235.
27. Weiss, J. M., Back, T. C., Scarzello, A. J., Subleski, J. J., Hall, V. L., Stauffer, J. K., Chen, X. et al., Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc. Natl. Acad. Sci. USA 2009. 106: 19455-19460.
28. Heusinkveld, M., de Vos van Steenwijk, P. J., Goedemans, R., Ramwadhdoebe, T. H., Gorter, A., Welters, M. J., van Hall, T. et al., M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J. Immunol. 2011. 187: 1157-1165.
29. Fridman, W. H., Pages, F., Sautes-Fridman, C. and Galon, J., The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 2012. 12: 298-306.
30. Ambarus, C. A., Krausz, S., van Eijk, M., Hamann, J., Radstake, T. R., Reedquist, K. A., Tak, P. P. et al., Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J. Immunol. Methods 2012. 375: 196-206.
31. Haswell, L. E., Glennie, M. J. and Al-Shamkhani, A., Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur. J. Immunol. 2001. 31: 3094-3100.
32. White, A. L., Chan, H. T., Roghanian, A., French, R. R., Mockridge, C. I., Tutt, A. L., Dixon, S. V. et al., Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 2011. 187: 1754-1763.
33. Lum, H. D., Buhtoiarov, I. N., Schmidt, B. E., Berke, G., Paulnock, D. M., Sondel, P. M. and Rakhmilevich, A. L., Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha. Immunology 2006. 118: 261-270.
34. Lin, E. Y., Nguyen, A. V., Russell, R. G. and Pollard, J. W., Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 2001. 193: 727-740.
35. Kennedy, M. K., Picha, K. S., Fanslow, W. C., Grabstein, K. H., Alderson, M. R., Clifford, K. N., Chin, W. A. et al., CD40/CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages. Eur. J. Immunol. 1996. 26: 370-378.
36. Conzelmann, M., Wagner, A. H., Hildebrandt, A., Rodionova, E., Hess, M., Zota, A., Giese, T. et al., IFN-gamma activated JAK1 shifts CD40-induced cytokine profiles in human antigen-presenting cells toward high IL-12p70 and low IL-10 production. Biochem. Pharmacol. 2010. 80: 2074-2086.
37. Chougnet, C., Thomas, E., Landay, A. L., Kessler, H. A., Buchbinder, S., Scheer, S. and Shearer, G. M., CD40 ligand and IFN-gamma synergistically restore IL-12 production in HIV-infected patients. Eur. J. Immunol. 1998. 28: 646-656.
38. Buhtoiarov, I. N., Lum, H., Berke, G., Paulnock, D. M., Sondel, P. M. and Rakhmilevich, A. L., CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J. Immunol. 2005. 174: 6013-6022.
39. Major, J., Fletcher, J. E. and Hamilton, T. A., IL-4 pretreatment selectively enhances cytokine and chemokine production in lipopolysaccharide-stimulated mouse peritoneal macrophages. J. Immunol. 2002. 168: 2456-2463.
40. Suk, K., Somers, S. D. and Erickson, K. L., Regulation of murine macrophage function by IL-4: IL-4 and IFN-gamma differentially regulate macrophage tumoricidal activation. Immunology 1993. 80: 617-624.
41. Pelegrin, P. and Surprenant, A., Dynamics of macrophage polarization reveal new mechanism to inhibit IL-1beta release through pyrophosphates. EMBO J. 2009. 28: 2114-2127.
42. Biswas, S. K., Gangi, L., Paul, S., Schioppa, T., Saccani, A., Sironi, M., Bottazzi, B. et al., A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006. 107: 2112-2122.
43. Tsai, C. S., Chen, F. H., Wang, C. C., Huang, H. L., Jung, S. M., Wu, C. J., Lee, C. C. et al., Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. Int. J. Radiat. Oncol. Biol. Phys. 2007. 68: 499-507.
44. Palucka, K. A., Taquet, N., Sanchez-Chapuis, F. and Gluckman, J. C., Dendritic cells as the terminal stage of monocyte differentiation. J. Immunol. 1998. 160: 4587-4595.
45. Kalinski, P., Smits, H. H., Schuitemaker, J. H., Vieira, P. L., van Eijk, M., de Jong, E. C., Wierenga, E. A. et al., IL-4 is a mediator of IL-12p70 induction by human Th2 cells: reversal of polarized Th2 phenotype by dendritic cells. J. Immunol. 2000. 165: 1877-1881.
46. Bullens, D. M., Kasran, A., Thielemans, K., Bakkus, M. and Ceuppens, J. L., CD40L-induced IL-12 production is further enhanced by the Th2 cytokines IL-4 and IL-13. Scand. J. Immunol. 2001. 53: 455-463.
47. Carvalho, L. H., Sano, G., Hafalla, J. C., Morrot, A., Curotto de Lafaille, M. A. and Zavala, F., IL-4-secreting CD4+ T cells are crucial to the development of CD8+ T-cell responses against malaria liver stages. Nat. Med. 2002. 8: 166-170.
48. Biedermann, T., Zimmermann, S., Himmelrich, H., Gumy, A., Egeter, O., Sakrauski, A. K., Seegmuller, I. et al., IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat. Immunol. 2001. 2: 1054-1060.